Janusz H.
- Country
- Poland
- Department
- 161602: Oddział Kliniczny Hematologii i Chorób Wewnętrznych z Ośrodkiem Transplantacji Szpiku
Research Overview
- Efficacy and Safety Evaluation of Glofitamab with Gemcitabine and Oxaliplatin Versus Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Non‑inferiority of nivolumab‑based N‑AVD versus brentuximab‑vedotin‑based BrECADD combination therapy as first‑line treatment in advanced Hodgkin lymphoma
- Evaluation of Tafasitamab and Lenalidomide Efficacy and Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Ineligible for HDC/ASCT
Data & Insights
Has run more than one trial at 241 of 453 partner sites.
Specializations
Hematologic Malignancies
Specialized in treating various forms of blood cancers and disorders, with particular focus on leukemia, lymphoma, and myeloma. Primary research interests include innovative therapies for chronic lymphocytic leukemia, acute myeloid leukemia, and diffuse large B-cell lymphoma.
- Multiple Myeloma Treatment Studies
- Mantle Cell Lymphoma Research
- Hodgkin Lymphoma Therapies
Myeloid Disorders
Focused on developing treatments for various myeloid conditions, particularly myelodysplastic syndromes and myelofibrosis. Research includes novel approaches to managing transfusion-dependent anemia and investigating new therapeutic combinations.
- Targeted Therapies for MDS
- Anemia Management Strategies
- Myelofibrosis Treatment Protocols
Solid Tumors
Investigates advanced treatment approaches for various solid tumors, including non-small cell lung cancer, esophageal squamous cell carcinoma, and gastric cancer. Research encompasses immunotherapy combinations and targeted treatments.
- Lung Cancer Immunotherapy
- Bladder Cancer Treatment
- Endometrial Cancer Studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.